2018
DOI: 10.3727/096504017x14841698396865
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Glioblastoma is a lethal disease featuring a high proliferation of tumor cells, excessive angiogenesis, and heavy drug resistance. The overall survival of glioblastoma patients has been dismal, even with an intensive standard of care. Recent advances in immune checkpoint blockades are changing the treatment of cancers. However, the efficacy of immune checkpoint blockades in glioblastoma is still unclear. Here we investigated the roles of CD103+ cells in regulating the effect of immune checkpoint blockades in g… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 32 publications
0
5
0
Order By: Relevance
“…The effects of Flt3L on anti-tumor and autoimmunity have been widely studied previously due to its ability to enhance the CD8 ? T cell response and facilitate formation of regulatory T (T reg ) cells, respectively, and increase the proliferation of DC as well (Svensson et al 2013;Gao et al 2018;Miao et al 2018). In addition, Flt3L was also widely used as an adjuvant of DNA vaccines to enhance the immunogenicity, especially the cellular immunity (Zhou et al 2010;Mwangi et al 2011;Xu et al 2016;Gao et al 2018).…”
Section: Discussionmentioning
confidence: 99%
“…The effects of Flt3L on anti-tumor and autoimmunity have been widely studied previously due to its ability to enhance the CD8 ? T cell response and facilitate formation of regulatory T (T reg ) cells, respectively, and increase the proliferation of DC as well (Svensson et al 2013;Gao et al 2018;Miao et al 2018). In addition, Flt3L was also widely used as an adjuvant of DNA vaccines to enhance the immunogenicity, especially the cellular immunity (Zhou et al 2010;Mwangi et al 2011;Xu et al 2016;Gao et al 2018).…”
Section: Discussionmentioning
confidence: 99%
“…cDC1 expand in number in response to in vivo administration of Flt3-L [161,162]. Combining Flt3-L and poly-I:C treatment induces expansion and activation of CD103 + cDC1 from DC progenitors within the tumor and enhances the efficacy of checkpoint therapy blockade in experimental models of melanoma [41] and glioblastoma [163]. In the context of DC vaccination, the addition of Flt3-L enhances the efficacy of RNA vaccination, with pDC rather than cDC1 essential for the adjuvant effect of Flt3-L in this setting [164].…”
Section: Modulating DC Generation and Migration During Cancer Therapymentioning
confidence: 99%
“…Previously, Miao et al 26 demonstrated that Flt3L can enhance the antitumor efficacy of immune checkpoint blockade by increasing the frequency of tumor-infiltrating CD8 + cells in a murine glioblastoma model. Similarly, Ho et al 27 demonstrated that a paucity of DC limits tumor responsiveness to immune checkpoint blockade but that Flt3L can rescue immune checkpoint blockade efficacy by increasing tumor-infiltrating DC in colorectal cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Lastly, we hypothesized that monocyte vaccination and Flt3L would significantly improve the antitumor efficacy of immune checkpoint blockade in a subcutaneous B16/F10-OVA murine melanoma model. Although previous studies have demonstrated Flt3L can be used to overcome tumor resistance to immune checkpoint blockade, [25][26][27] to our knowledge, this relationship has not been studied in combination with therapeutic cancer vaccination. Ultimately, the triple immunotherapy strategy proposed here has the potential to improve antitumor immune responses and broaden the spectrum of melanoma patients who respond to immune checkpoint blockade.…”
mentioning
confidence: 95%